Established in 2001, Genzyme Ireland is situated on a 37 acre site in Waterford. This multi phased Biopharmaceutical facility has a capital investment of over €400 million and employs over 450 personnel. It is a state-of-the-art facility for finishing of biopharmaceuticals and employs a high level of automation, including Manufacturing Execution Systems.
The first phase of development, a tabletting suite with packaging lines, for manufacture of Renagel has been supplying product to Dialysis patients globally since 2003.
The Biologics Fill Finish facility commenced commercial supply of thymoglobulin in 2006 to global markets. This facility uses isolator technology in its aseptic process.
The third manufacturing plant commenced operations in 2009. This facility enabled the expansion of our Oral Dose capacity allowing a number of new product introductions.
New products introduced during 2010 in both biologics and oral dose, brought to 8 the products being supplied globally to our patients.
In February 2008 the site finalised plans to expand it’s Biological Fill/Finish operations and associated site infrastructure. This expansion will bring the total investment on site to over €400 million.
These are exciting times for Genzyme Ireland as we continue to ramp up our manufacturing output, whilst continuing to increase our employment and continue to invest in the site infrastructure.